Landmark Bio began construction in July of 2021 on a leased facility in Watertown, Mass. Supported by $76 million in funding, the 40,000-sf project will accelerate the availability of novel therapeutics by collocating research, development, manufacturing, and commercialization activities in the same structure. Featuring eight GMP cleanrooms configured to allow production of both cell and viral vector materials, the center will include labs, offices, and quality control suites. Cross-industry interaction venues will enable academic, medical, and pharmaceutical partners to collaboratively discover new cell and gene therapies, immunotherapy treatments, and gene editing technologies. The facility will also accommodate training programs to build a talent pipeline for skilled workers. Occupancy is expected in early 2022. Alexandria Real Estate Equities is the owner and developer of the existing structure, which is located in the Arsenal on the Charles development.
Landmark Bio is a public-private partnership led by Harvard University and MIT. Other founding members include Cytiva and Fujifilm Diosynth Biotechnologies.
